Suchergebnisse - "Frisell, Thomas"

PubPharm (6)

1

Influenza outcomes in patients with inflammatory joint diseases and DMARDs : how do they compare to those of COVID-19?

enthalten in: Annals of the rheumatic diseases | 2022

von Bower, H. | Frisell, T. | Di Giuseppe, D. | +2

2

Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis

enthalten in: JAMA neurology | 2020

von Brauner, S. | Eriksson-Dufva, A. | Hietala, M. | +3

3

Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry

enthalten in: Multiple sclerosis (Houndmills, Basingstoke, England) | 2018

von Spelman, T. | Frisell, T. | Piehl, F. | +1

4

How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries

enthalten in: Annals of the rheumatic diseases | 2016

von Askling, J. | Berglind, N. | Franzen, S. | +17

5

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

enthalten in: Annals of neurology | 2016

von Alping, P. | Frisell, T. | Novakova, L. | +9

CommentIn: Ann Neurol. 2016 Nov;80(5):791-792. - PMID 27553863

6

Methodological Challenges When Comparing Demographic and Clinical Characteristics of International Observational Registries

enthalten in: Arthritis care & research | 2015

von Verstappen, S. | Askling, J. | Berglind, N. | +16

1
[1]